Paper7494331
Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.
Heineman TC and 4 others. J Virol, 1995. Cited by 42 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Papers, record 7494331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7494331
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs.
- PubMed
Topics14
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Herpes Genitalis | Major topic |
| Herpesvirus 2, Human | Major topic |
| Herpesvirus 3, Human | Major topic |
| Vaccines, Synthetic | Major topic |
| Viral Envelope Proteins | Major topic |
| Viral Vaccines | Major topic |
| Animals | |
| Blotting, Southern | |
| DNA, Viral | |
| Female | |
| Guinea Pigs | |
| Humans | |
| Immunization | |
| Microscopy, Immunoelectron |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| AI15101 | NIAID NIH HHS | United States | R01AI015101 | PubMed and NIH | NIH RePORTER |
| AI22667 | NIAID NIH HHS | United States | R01AI022667 | PubMed and NIH | NIH RePORTER |
| AI29687 | NIAID NIH HHS | United States | R01AI029687 | PubMed and NIH | NIH RePORTER |
References27
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 2,833,603 | A herpes simplex virus mutant in which glycoprotein D sequences are replaced by beta-galactosidase sequences binds to but is unable to penetrate into cells. | J Virol | 1988 | https://conductscience.org/library/papers/2833603 | PubMed |
| 2 | 2,826,603 | Herpes simplex virus glycoprotein treatment of recurrent genital herpes. | J Infect Dis | 1988 | https://conductscience.org/library/papers/2826603 | PubMed |
| 3 | 1,973,187 | Herpes simplex virus glycoprotein D is recognized as antigen by CD4+ and CD8+ T lymphocytes from infected mice. Characterization of T cell clones. | J Immunol | 1990 | https://conductscience.org/library/papers/1973187 | PubMed |
| 4 | 1,849,161 | Varicella in hairless guinea pigs. | J Infect Dis | 1991 | https://conductscience.org/library/papers/1849161 | PubMed |
| 5 | 1,646,279 | Development of immunogenic recombinant Oka varicella vaccine expressing hepatitis B virus surface antigen. | J Gen Virol | 1991 | https://conductscience.org/library/papers/1646279 | PubMed |
| 6 | 1,320,650 | Animal models of varicella. | J Infect Dis | 1992 | https://conductscience.org/library/papers/1320650 | PubMed |
| 7 | 1,321,283 | Herpes simplex virus type 1 entry through a cascade of virus-cell interactions requires different roles of gD and gH in penetration. | J Virol | 1992 | https://conductscience.org/library/papers/1321283 | PubMed |
| 8 | 1,335,196 | Current status and prospects of live varicella vaccine. | Vaccine | 1992 | https://conductscience.org/library/papers/1335196 | PubMed |
| 9 | 8,387,560 | Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. | J Infect Dis | 1993 | https://conductscience.org/library/papers/8387560 | PubMed |
| 10 | 8,394,020 | Generation of varicella-zoster virus (VZV) and viral mutants from cosmid DNAs: VZV thymidylate synthetase is not essential for replication in vitro. | Proc Natl Acad Sci U S A | 1993 | https://conductscience.org/library/papers/8394020 | PubMed |
| 11 | 8,151,792 | Deletion of the varicella-zoster virus large subunit of ribonucleotide reductase impairs growth of virus in vitro. | J Virol | 1994 | https://conductscience.org/library/papers/8151792 | PubMed |
| 12 | 7,911,177 | Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. | Lancet | 1994 | https://conductscience.org/library/papers/7911177 | PubMed |
| 13 | 7,964,618 | Absence of varicella-zoster virus (VZV) glycoprotein V does not alter growth of VZV in vitro or sensitivity to heparin. | J Gen Virol | 1994 | https://conductscience.org/library/papers/7964618 | PubMed |
| 14 | 7,966,575 | Varicella-zoster virus (VZV) open reading frame 10 protein, the homolog of the essential herpes simplex virus protein VP16, is dispensable for VZV replication in vitro. | J Virol | 1994 | https://conductscience.org/library/papers/7966575 | PubMed |
| 15 | 7,856,096 | Varicella-zoster virus open reading frame 1 encodes a membrane protein that is dispensable for growth of VZV in vitro. | Virology | 1995 | https://conductscience.org/library/papers/7856096 | PubMed |
| 16 | 80,458 | Type-common CP-1 antigen of herpes simplex virus is associated with a 59,000-molecular-weight envelope glycoprotein. | J Virol | 1978 | https://conductscience.org/library/papers/80458 | PubMed |
| 17 | 6,286,797 | Genital herpes in guinea pigs: pathogenesis of the primary infection and description of recurrent disease. | J Infect Dis | 1982 | https://conductscience.org/library/papers/6286797 | PubMed |
| 18 | 6,323,270 | DNA sequence of the Herpes simplex virus type 2 glycoprotein D gene. | Gene | 1983 | https://conductscience.org/library/papers/6323270 | PubMed |
| 19 | 2,983,428 | Protection from genital herpes simplex virus type 2 infection by vaccination with cloned type 1 glycoprotein D. | Science | 1985 | https://conductscience.org/library/papers/2983428 | PubMed |
| 20 | 3,016,155 | Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. | J Gen Virol | 1986 | https://conductscience.org/library/papers/3016155 | PubMed |
Cited by12
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 38,003,300 | The Quest for Immunity: Exploring Human Herpesviruses as Vaccine Vectors. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/38003300 | PubMed |
| 36,560,823 | Recombinant Simian Varicella Virus-Simian Immunodeficiency Virus Vaccine Induces T and B Cell Functions and Provides Partial Protection against Repeated Mucosal SIV Challenges in Rhesus Macaques. | Viruses | 2022 | https://conductscience.org/library/papers/36560823 | PubMed |
| 23,843,791 | Recombinant varicella-zoster virus vaccines as platforms for expression of foreign antigens. | Adv Virol | 2013 | https://conductscience.org/library/papers/23843791 | PubMed |
| 22,133,885 | HSV-2: in pursuit of a vaccine. | J Clin Invest | 2011 | https://conductscience.org/library/papers/22133885 | PubMed |
| 20,225,013 | The varicella-zoster virus genome. | Curr Top Microbiol Immunol | 2010 | https://conductscience.org/library/papers/20225013 | PubMed |
| 18,272,766 | Recombinant simian varicella viruses expressing respiratory syncytial virus antigens are immunogenic. | J Gen Virol | 2008 | https://conductscience.org/library/papers/18272766 | PubMed |
| 17,627,531 | Prophylactic vaccine strategies and the potential of therapeutic vaccines against herpes simplex virus. | Curr Pharm Des | 2007 | https://conductscience.org/library/papers/17627531 | PubMed |
| 15,138,167 | Herpes simplex virus type 2 vaccines: new ground for optimism? | Clin Diagn Lab Immunol | 2004 | https://conductscience.org/library/papers/15138167 | PubMed |
| 11,991,985 | Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. | J Virol | 2002 | https://conductscience.org/library/papers/11991985 | PubMed |
| 11,152,015 | Current recommendations for the treatment of genital herpes. | Drugs | 2000 | https://conductscience.org/library/papers/11152015 | PubMed |
| 10,195,045 | Control of STDs--the role of prophylactic vaccines against herpes simplex virus. | Sex Transm Infect | 1998 | https://conductscience.org/library/papers/10195045 | PubMed |
| 8,876,149 | Immunization with DNA vaccines encoding glycoprotein D or glycoprotein B, alone or in combination, induces protective immunity in animal models of herpes simplex virus-2 disease. | Proc Natl Acad Sci U S A | 1996 | https://conductscience.org/library/papers/8876149 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| ACKR1 | 2,532 | PubTator's text mining | https://conductscience.org/library/genes/2532 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/7494331
GET https://conductscience.org/api/papers/v1/7494331/references?page=2